title: Engineering tolerance using biomaterials to target and control antigen presenting cells.
abstract: Autoimmune diseases occur when cells of the adaptive immune system incorrectly recognize and attack "self" tissues. Importantly, the proliferation and differentiation of these cells is triggered and controlled by interactions with antigen presenting cells (APCs), such as dendritic cells. Thus, modulating the signals transduced by APCs (e.g., cytokines, costimulatory surface proteins) has emerged as a promising strategy to promote tolerance for diseases such as multiple sclerosis, type 1 diabetes, and lupus. However, many approaches have been hindered by non-specific activity of immunosuppressive or immunoregulatory cues, following systemic administration of soluble factors via traditional injections routes (e.g., subcutaneous, intravenous). Biomaterials offer a unique opportunity to control the delivery of tolerogenic signals in vivo via properties such as controlled particle size, tunable release kinetics, and co-delivery of multiple classes of cargo. In this review, we highlight recent reports that exploit these properties of biomaterials to target APCs and promote tolerance via three strategies, i) passive or active targeting of particulate carriers to APCs, ii) biomaterial-mediated control over antigen localization and processing, and iii) targeted delivery of encapsulated or adsorbed immunomodulatory signals. These reports represent exciting advances toward the goal of more effective therapies for autoimmune diseases, without the broad suppressive effects associated with current clinically-approved therapies.
authors.affiliation: Fischell Department of Bioengineering, University of Maryland, 8228 Paint Branch Dr., College Park, MD 20742, USA.
authors.forename: Lisa H
authors.initials: LH
authors.lastname: Tostanoski
authors.affiliation: Fischell Department of Bioengineering, University of Maryland, 8228 Paint Branch Dr., College Park, MD 20742, USA.
authors.forename: Emily A
authors.initials: EA
authors.lastname: Gosselin
authors.affiliation: Fischell Department of Bioengineering, University of Maryland, 8228 Paint Branch Dr., College Park, MD 20742, USA.|Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 West Baltimore St., Baltimore, MD 21201, USA.|Marlene and Stewart Greenebaum Cancer Center, 22 S. Greene St., Baltimore, MD 21201, USA.
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Jewell
mesh_terms: D000818:Animals; D001324:Autoantigens / Q000187:drug effects; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D057005:Bioengineering / Q000379:methods; D002454:Cell Differentiation / Q000187:drug effects; D016207:Cytokines / Q000276:immunology; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D016503:Drug Delivery Systems / Q000379:methods; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D007155:Immunologic Factors / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D008180:Lupus Erythematosus, Systemic / Q000628:therapy*; D009103:Multiple Sclerosis / Q000628:therapy*; D010316:Particle Size
chemical_list: D001324:Autoantigens; D001672:Biocompatible Materials; D016207:Cytokines; D007155:Immunologic Factors